7 Matching Annotations
  1. Last 7 days
    1. Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas

      [Paper-level Aggregated] PMCID: PMC3727232

      Evidence Type(s): Oncogenic, Predictive, Prognostic

      Justification: Oncogenic: The presence of BRAF:p.V600E mutations and H3F3A:p.K27M mutations in various tumor types suggests that these variants are associated with oncogenesis, as they recur in specific histopathological subtypes and are linked to tumor development. Predictive: The identification of BRAF:p.V600E mutations in a high proportion of pleomorphic xanthoastrocytomas indicates that this variant may predict response to targeted therapies that inhibit the BRAF pathway. Prognostic: The frequency of BRAF:p.V600E mutations in different tumor types, particularly in pleomorphic xanthoastrocytomas, may provide prognostic information regarding tumor behavior and patient outcomes.

      Gene→Variant (gene-first): H3-3B(3021):p.K27M BRAF(673):p.V600E

      Genes: H3-3B(3021) BRAF(673)

      Variants: p.K27M p.V600E

    2. Across the study cohort of 151 tumors (Figs. 2-4; Supplementary Table 4), KIAA1549-BRAF fusions were detected in PAs, two pilomyxoid astrocytomas (PMAs), and a single brainstem ganglioglioma, and were present in 59%, 90%

      [Paragraph-level] PMCID: PMC3727232 Section: RESULTS PassageIndex: 11

      Evidence Type(s): Diagnostic, Oncogenic

      Justification: Diagnostic: The passage discusses the detection of BRAF:p.V600E mutations in various tumor types, indicating its association with specific tumor classifications, which supports its use as a biomarker for diagnosis. Oncogenic: The H3F3A:p.K27M mutation is described as being present in specific tumor types, indicating its contribution to tumor development or progression.

      Gene→Variant (gene-first): 3021:p.K27M 673:p.V600E

      Genes: 3021 673

      Variants: p.K27M p.V600E

    3. Only four of 39 tumors (10%) in the WGS series lacked a MYB/MYBL1 rearrangement, FGFR1 alteration, or aberration of a gene in the NF1/RAS/RAF pathway. One of these, SJLGG034, was an oligodendroglioma from a patient aged

      [Paragraph-level] PMCID: PMC3727232 Section: RESULTS PassageIndex: 6

      Evidence Type(s): None

      Justification: Not enough information in this passage.

      Gene→Variant (gene-first): 1106:p.D1722V 1029:p.P101L 3417:p.R132H 23152:p.S726R 23152:p.V676fs

      Genes: 1106 1029 3417 23152

      Variants: p.D1722V p.P101L p.R132H p.S726R p.V676fs

    4. Remarkably, the median number of non-silent somatic sequence mutations and SVs per tumor in the WGS (discovery) series was one, suggesting that few genetic alterations are required for oncogenesis (Fig. 1; Supplementary

      [Paragraph-level] PMCID: PMC3727232 Section: RESULTS PassageIndex: 5

      Evidence Type(s): Oncogenic, Diagnostic

      Justification: Oncogenic: The passage discusses the H3F3A:p.K27M mutation and BRAF:p.V600E mutation as recurrent abnormalities in specific tumor types, indicating their contribution to tumor development or progression. Diagnostic: The mention of BRAF:p.V600E mutations being frequent in pleomorphic xanthoastrocytomas suggests its use in defining or classifying this subtype of tumor.

      Gene→Variant (gene-first): 3021:p.K27M 673:p.V600E

      Genes: 3021 673

      Variants: p.K27M p.V600E

    5. Across the study cohort of 151 tumors (Figs. 2-4; Supplementary Table 4), KIAA1549-BRAF fusions were detected in PAs, two pilomyxoid astrocytomas (PMAs), and a single brainstem ganglioglioma, and were present in 59%, 90%

      [Paragraph-level] PMCID: PMC3727232 Section: RESULTS PassageIndex: 11

      Evidence Type(s): Diagnostic, Oncogenic

      Justification: Diagnostic: The passage discusses the detection of BRAF:p.V600E mutations in various tumor types, indicating its association with specific tumor classifications, which supports its use as a biomarker for diagnosis. Oncogenic: The H3F3A:p.K27M mutation is described as being present in specific tumor types, indicating its contribution to tumor development or progression.

      Gene→Variant (gene-first): 3021:p.K27M 673:p.V600E

      Genes: 3021 673

      Variants: p.K27M p.V600E

    6. Only four of 39 tumors (10%) in the WGS series lacked a MYB/MYBL1 rearrangement, FGFR1 alteration, or aberration of a gene in the NF1/RAS/RAF pathway. One of these, SJLGG034, was an oligodendroglioma from a patient aged

      [Paragraph-level] PMCID: PMC3727232 Section: RESULTS PassageIndex: 6

      Evidence Type(s): None

      Justification: Not enough information in this passage.

      Gene→Variant (gene-first): 1106:p.D1722V 1029:p.P101L 3417:p.R132H 23152:p.S726R 23152:p.V676fs

      Genes: 1106 1029 3417 23152

      Variants: p.D1722V p.P101L p.R132H p.S726R p.V676fs

    7. Remarkably, the median number of non-silent somatic sequence mutations and SVs per tumor in the WGS (discovery) series was one, suggesting that few genetic alterations are required for oncogenesis (Fig. 1; Supplementary

      [Paragraph-level] PMCID: PMC3727232 Section: RESULTS PassageIndex: 5

      Evidence Type(s): Oncogenic, Diagnostic

      Justification: Oncogenic: The passage discusses the H3F3A:p.K27M mutation and BRAF:p.V600E mutation as recurrent abnormalities in specific tumor types, indicating their contribution to tumor development or progression. Diagnostic: The mention of BRAF:p.V600E mutations being frequent in pleomorphic xanthoastrocytomas suggests its use in defining or classifying this subtype of tumor.

      Gene→Variant (gene-first): 3021:p.K27M 673:p.V600E

      Genes: 3021 673

      Variants: p.K27M p.V600E